Related Experiment Video

Updated: Jun 8, 2026

Embolic Middle Cerebral Artery Occlusion (MCAO) for Ischemic Stroke with Homologous Blood Clots in Rats
09:11

Embolic Middle Cerebral Artery Occlusion (MCAO) for Ischemic Stroke with Homologous Blood Clots in Rats

Published on: September 17, 2014

Association of apolipoprotein M gene polymorphisms with ischemic stroke in a Han Chinese population

Dongxue Zhao1, Zhiyi He, Xue Qin

  • 1Department of Neurology, Sheng Jing Hospital of China Medical University, Shenyang, 110001, China.

Journal of Molecular Neuroscience : MN
|September 28, 2010
PubMed

Insights

Genetic variations in the apolipoprotein M (ApoM) gene, specifically T-778C and C-1065A single-nucleotide polymorphisms (SNPs), are linked to an increased risk of ischemic stroke in the Han Chinese population.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Molecular Biology

Background:

  • Apolipoprotein M (ApoM) plays a key role in high-density lipoprotein (HDL) metabolism and cholesterol transport.
  • Single-nucleotide polymorphisms (SNPs) in genes can influence susceptibility to complex diseases like ischemic stroke.
  • Understanding the genetic basis of ischemic stroke is crucial for developing targeted prevention strategies.

Purpose of the Study:

  • To investigate the association between specific apolipoprotein M (ApoM) gene single-nucleotide polymorphisms (SNPs) and the risk of ischemic stroke.
  • To evaluate the relationship between ApoM gene variants and plasma lipid levels in ischemic stroke patients and healthy controls.

Main Methods:

  • A case-control study was conducted involving 314 ischemic stroke patients and 389 healthy controls.
  • Genotyping of three ApoM gene SNPs (C-1065A, T-855C, and T-778C) was performed using a SNaPshot Multiplex sequencing assay.
  • Statistical analyses were employed to compare genotype and allele frequencies and adjust for confounding factors.

Main Results:

  • The T-855C SNP showed no significant difference in genotype or allele frequencies between patients and controls.
  • Significantly higher frequencies of the TC genotype (T-778C), C allele (T-778C), and A allele (C-1065A) were observed in ischemic stroke patients compared to controls.
  • After adjusting for hypertension, diabetes, smoking, and alcohol consumption, the TC genotype of T-778C and the A allele of C-1065A remained associated with increased ischemic stroke risk.
  • Higher total cholesterol levels were found in controls with CC or CT genotypes of T-778C compared to those with the TT genotype.

Conclusions:

  • The ApoM gene T-778C and C-1065A SNPs are associated with an increased risk of ischemic stroke in the Han Chinese population.
  • These specific ApoM gene variants may contribute to the pathogenesis of ischemic stroke, potentially through alterations in cholesterol metabolism.

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...